BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

Public knowledge, attitude, and acceptance toward COVID-19 vaccines in Palestine: a cross-sectional study
The consequences of the COVID-19 pandemic on physical and mental health in addition to the global economy are huge. Vaccination is a pivotal measure to decrease COVID-19 morbidity and mortality and to help bri…
Authors: Mohammed Al-kafarna, Sajeda Ghassan Matar, Hossam Waleed Almadhoon, Bashar Khaled Almaghary, Mohamed Sayed Zaazouee, Asmaa Ahmed Elrashedy, Dalia Sami Wafi, Sami D. Jabari, Omar H. Salloum, Eman Ahmed Ibrahim, Hala ZI Alagha and Elfatih A. Hasabo
Citation: BMC Public Health 2022 22:529
Content type: Research Published on: 17 March 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

Public perception of isolation, quarantine, social distancing and community containment during COVID-19 pandemic
Effective strategies of prevention have been and can aid in reducing and overcoming contagious diseases including COVID-19, still there is dearth of knowledge regarding general public awareness and perception….
Authors: Tahreem Hussain, Nida Jawed, Saba Mughal and Kashif Shafique
Citation: BMC Public Health 2022 22:528
Content type: Research Published on: 17 March 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

Determinants of pentavalent and measles vaccination dropouts among children aged 12–23 months in The Gambia
Every year, vaccination averts about 3 million deaths from vaccine-preventable diseases (VPDs). However, despite that immunization coverage is increasing globally, many children in developing countries are sti…
Authors: Peter A. M. Ntenda, Alick Sixpence, Tisungane E. Mwenyenkulu, Kondwani Mmanga, Angeziwa C. Chirambo, Andy Bauleni and Owen Nkoka
Citation: BMC Public Health 2022 22:520
Content type: Research Published on: 17 March 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

How (not) to mobilize health workers in the fight against vaccine hesitancy: Experimental evidence from Germany’s AstraZeneca controversy
COVID-19 vaccine hesistancy is a serious policy issue in Germany as vaccinations have stagnated at low levels compared to most other European countries. In this context, we study whether and how health workers…
Authors: Jan Priebe, Henning Silber, Christoph Beuthner and Steffen Pötzschke
Citation: BMC Public Health 2022 22:516
Content type: Research Published on: 16 March 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

Ethical challenges and moral distress among field epidemiologists
As ‘disease detectives’ and directors of public health programs, field epidemiologists play essential roles in protecting public health. Although ethical issues receive considerable attention in medical and re…
Authors: Emma Cooke, George Lopez, Angela Hilmers and David G. Addiss
Citation: BMC Public Health 2022 22:510
Content type: Research Published on: 16 March 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 19 Mar 2022)

Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave
The novel coronavirus pandemic (COVID-19) has had severe impacts on morbidity and mortality globally.
Authors: Naomi J. Patterson, Valerie A. Paz-Soldan, Richard Oberhelman, Lina Moses, Aubrey Madkour and Thomas T. Miles
Citation: BMC Public Health 2022 22:503

Cell
Mar 17, 2022 Volume 18 5 Issues 6 p939-1104
https://www.cell.com/cell/current

Articles
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Katharina Röltgen, et al
Open Access
Human antibody responses to SARS-CoV-2 differ between vaccination and infection, with mRNA vaccination inducing more productive lymph node GC responses and several vaccine types stimulating IgG antibodies capable of recognizing a broader range of viral variants.

Clinical Therapeutics
January 2022 Volume 44 Issue 1 p1-154
http://www.clinicaltherapeutics.com/current

Reviews
Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health—an EFPIA View
Esteban Herrero-Martinez, Nasir Hussain, Nadege Le Roux,…Mark Mayer, Rodrigo Palacios, Thomas C. Kühler
Published online: November 27, 2021
p132-138
Open Access
ABSTRACT
The European Union regulatory framework supports development, review, authorization, and maintenance of medicines to benefit public health; however, many elements are 2 decades old and undergoing review. Scrutiny was triggered by the coronavirus disease 2019 pandemic, the need to support future innovative medicines, the digital transformation of data exchange, and the need to address efficiency and capacity limitations. There are also ongoing evolutions in regulatory science for medicines (eg, cell and gene therapies), medical device combinations, and software, as well as the need to fully leverage contemporary information technology (IT). Important initiatives to address these challenges include the European Medicines Agency (EMA) Regulatory Science Strategy,¹ the EU Regulatory Network Strategy,² and the Big Data Steering Group,³ alongside European Commission–led initiatives such as the Pharmaceutical Strategy.⁴
Dynamic regulatory assessment (DRA) is a concept that seeks to integrate these various elements to re-imagine regulatory review interactions across the product life cycle. DRA calls for iterative regulatory dialogue, data submission, and evidence assessment, enabled by contemporary IT. DRA will facilitate iterative interaction and data assessment as it accumulates over a product’s life cycle, bringing significant efficiencies for all product types. The DRA concept primarily evolved through dialogue within working groups of the European Federation of Pharmaceutical Industries and Associations. This article describes the long-term vision of the European Federation of Pharmaceutical Industries and Associations and outlines important strategic elements of progress, including: aligning on a multi-stakeholder vision for DRA in the European Union and across regions; leveraging learnings from ongoing initiatives; and advancing IT, governance, and standards considerations. Ultimately, DRA should consider outcomes that deliver optimal benefits for patients in the European Union and worldwide.

Clinical Therapeutics
January 2022 Volume 44 Issue 1 p1-154
http://www.clinicaltherapeutics.com/current

Original Research
Willingness to Accept Expedited COVID-19 Vaccine Research for Children Aged <12 Years After Adult Vaccine Approval
Ran D. Goldman, Jeffrey N. Bone, Renana Gelernter,… Mark A. Griffiths, Ahmed Mater, for the International COVIPAS (COVID-19 Parental Attitude Study) Group
Published online: November 15, 2021
ABSTRACT
Purpose
The goal of this study was to assess if caregivers’ attitudes toward the regulatory process of approving the vaccine against coronavirus disease 2019 (COVID-19) for children aged <12 years changed after a vaccine was approved for adults. Methods This was a larger scale COVIPAS (COVID-19 Parental Attitude Study) survey of caregivers presenting with their children aged ≤12 years for emergency care in 12 hospitals in the United States, Canada, and Israel. The study compared willingness to support abridged research into COVID-19 vaccines for children between the peak of the pandemic (March–May 2020) and after a COVID-19 vaccine became available for adults (December 2020–March 2021). Findings A total of 1956 surveys were included in the analyses. Overall, 385 (30.9%) caregivers in the pre–vaccine approval period and 250 (35.3%) caregivers in the post–adult vaccine phase supported abridged research into COVID-19 vaccines (P < 0.001). In both phases, mothers were less likely to favor abridged approval. Those with children who were fully vaccinated based on the pediatric schedule in their country favored abridged approval in phase 1 (odds ratio, 1.98; 95% confidence interval, 1.31–3.08) but less so in phase 2. In both phases, age and concerns of parents that they had COVID-19 or their child had COVID-19 were not associated with changes in response between phases. Implications Willingness to expedite vaccine approval increased after the emergency approval of COVID-19 vaccine for adults. Mothers are much less likely to approve expedited approval. No significant changes have been found in the composition of caregivers willing to forego regulatory demands on vaccine approval.

Global Public Health
Volume 17, Issue 4 (2022)
http://www.tandfonline.com/toc/rgph20/current

Article
European Union: Commission Proposes Directive to Establish Due Diligence Procedures in Global Value Chains to Safeguard Human Rights and the Environment
On February 23, 2022, the European Commission published a proposal for a Directive on Corporate Sustainability Due Diligence. The directive would lay down rules for companies with regard to actual and potential adverse human rights and environmental impacts on their own and their subsidiaries’ operations and within their value chains, as well as establish rules … Continue reading “European Union: Commission Proposes Directive to…
Contributor: Gesley, Jenny
Date: 2022-03-15

Global Public Health
Volume 17, Issue 4 (2022)
http://www.tandfonline.com/toc/rgph20/current

Article Commentary
Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries
Ateeb Ahmad Parray, Uday Narayan Yadav, Anupom Das, ARM Mehrab Ali, Shemana Mollick, Senjuti Saha & Sabuj Kanti Mistry
Pages: 614-621
Published online: 20 Jan 2022

Global Public Health
Volume 17, Issue 4 (2022)
http://www.tandfonline.com/toc/rgph20/current

Article Commentary
Unresolved COVID Controversies: ‘Normal science’ and potential non-scientific influences
Carlos F. Cáceres
Pages: 622-640
Published online: 15 Feb 2022

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 19 Mar 2022]

Possibility of COVID-19 eradication with evolution of a new omicron variant
COVID-19 has been a global health concern since 2019 until date. Global concerted efforts to combat this pandemic has resulted in a number of vaccines distributed across the globe. Although the presence of the…
Authors: Moses Okpeku
Citation: Infectious Diseases of Poverty 2022 11:30
Content type: Commentary Published on: 14 March 2022

JAMA
March 15, 2022, Vol 327, No. 11, Pages 1011-1100
https://jamanetwork.com/journals/jama/currentissue

Original Investigation
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance
Amadea Britton, MD; Katherine E. Fleming-Dutra, MD; Nong Shang, PhD; et al.
free access has active quiz
JAMA. 2022;327(11):1032-1041. doi:10.1001/jama.2022.2068
This study estimates the associations between symptomatic SARS-CoV-2 infection and receipt of BNT162b2, mRNA-1273, and Ad26.COV2.S by day since vaccination before and during Delta variant predominance.

JAMA
March 15, 2022, Vol 327, No. 11, Pages 1011-1100
https://jamanetwork.com/journals/jama/currentissue

Research Letter
Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19
Jennifer L. Alejo, MD; Jonathan Mitchell, MBBS; Amy Chang, MD; et al.
free access has active quiz
JAMA. 2022;327(11):1085-1087. doi:10.1001/jama.2022.1393
This study uses serologic testing to characterize natural immunity and the long-term durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19 infection.

JAMA
March 15, 2022, Vol 327, No. 11, Pages 1011-1100
https://jamanetwork.com/journals/jama/currentissue

Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection
Lydia L. Shook, MD; Caroline G. Atyeo, BS; Lael M. Yonker, MD; et al.
free access has active quiz
JAMA. 2022;327(11):1087-1089. doi:10.1001/jama.2022.1206
This study compares the persistence of anti-spike IgG titers in infants of vaccinated mothers vs mothers who had been naturally infected with COVID-19.

JAMA
March 15, 2022, Vol 327, No. 11, Pages 1011-1100
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
Navigating Clinical and Business Ethics While Sharing Patient Data
Kelly N. Michelson, MD, MPH; James G. Adams, MD; Joshua M. M. Faber, BA
free access
JAMA. 2022;327(11):1025-1026. doi:10.1001/jama.2022.1942
This Viewpoint discusses the gap between clinical medical ethics and some business practices related to patient data sharing and secondary use of data by corporations.

JAMA Network
COVID-19 Update March 19, 2022

These articles on COVID-19 were published across the JAMA Network in the last week.

The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Nigeria: rightly taking its place on the world stage
The Lancet
Nigeria is emerging as a world power. It has great intellectual, cultural, and social capital, as well as financial assets. It dominates west Africa, having more than half of the region’s population, and has the highest gross domestic product on the continent. The population of more than 200 million is projected to double by 2050, and to reach 733 million by 2100—making Nigeria the third most populous country in the world, after China and India. This rapid population growth has been accelerated by falling infant mortality combined with a steady birth rate and can create a demographic dividend for Nigeria. But to take advantage of this situation, appropriate investments in health, education, and skills need to be made. Published today, The Lancet Nigeria Commission: investing in health and the future of the nation, views this human potential and extraordinary opportunity through a health lens, telling the story of Nigeria as shaped by the country’s history and present circumstances. Written by a team of experts working at institutions across the country, and members of the diaspora, it has been led by Nigerians for Nigerians.
This potential might not be realised if the country does not address intractable poverty and extreme inequality. Recent trends in health outcomes, as detailed in the accompanying Article published today, record 20 years of increased healthy life expectancy (although it is still low within the region, at 56 years), reductions in mortality for males and females of all ages, and rises in health expenditure but, overall, health outcomes are still poor. Nigeria has repeatedly failed to realise the health gains promised by multiple political leaders, and this failure is holding the country back…

The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

Articles
Population health outcomes in Nigeria compared with other west African countries, 1998–2019: a systematic analysis for the Global Burden of Disease Study
Blake Angell, at al
Open Access

The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

Articles
Population health outcomes in Nigeria compared with other west African countries, 1998–2019: a systematic analysis for the Global Burden of Disease Study
Blake Angell, at al
Open Access

The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study
Linda-Gail Bekker, et al. the Sisonke Protocol Team, on behalf of the Sisonke Study Team

The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

The Lancet Commissions
The Lancet Nigeria Commission: investing in health and the future of the nation
Ibrahim Abubakar, et al.
Open Access

Nature
Volume 603 Issue 7901, 17 March 2022
https://www.nature.com/nature/volumes/603/issues/7901

Article | 31 January 2022 | Open Access
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
Current vaccines induce broadly cross-reactive cellular immunity against SARS-CoV-2 variants, including Omicron, and provide protection against severe disease despite a substantially reduced neutralizing antibody response.
Jinyan Liu, Abishek Chandrashekar, Dan H. Barouch

Nature Biotechnology
Volume 40 Issue 3, March 2022
https://www.nature.com/nbt/volumes/40/issues/3

Patents | 16 March 2022
Contractual solutions to overcome drug scarcity during pandemics and epidemics
Licensing provisions that obligate recipients of government funding to share relevant technology and know-how for scarce drugs during pandemics and epidemics can reduce shortages and overcome obstacles that intellectual property rights present.
Sapna Kumar
Ana Santos Rutschman

Nature Biotechnology
Volume 40 Issue 3, March 2022
https://www.nature.com/nbt/volumes/40/issues/3

Article | 18 August 2021
Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children
Single-cell sequencing reveals pre-activated immunity as important for milder COVID-19 symptoms in children.
J. Loske, J. Röhmel. I. Lehmann

Nature Genetics
Volume 54 Issue 3, March 2022
https://www.nature.com/ng/volumes/54/issues/3

Editorial | 14 March 2022
Rare diseases, common challenges
The genetics community has a particularly important part to play in accelerating rare disease research and contributing to improving diagnosis and treatment. Innovations in sequencing technology and machine learning approaches have positively affected diagnostic success, but more coordinated efforts are needed to move towards effective therapies or even cures for these important, and sometimes overlooked, class of diseases.

Nature Genetics
Volume 54 Issue 3, March 2022
https://www.nature.com/ng/volumes/54/issues/3

Comment | 07 March 2022
A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States
To build a more efficient, equitable and sustainable approach to rare disease research in the United States, we must prioritize integrated research infrastructure and approaches that focus on understanding connections across rare diseases.
Meghan C. Halley, Hadley Stevens Smith, Holly K. Tabor

Nature Reviews Drug Discovery
Volume 21 Issue 3, March 2022
https://www.nature.com/nrd/volumes/21/issues/3

Comment | 28 January 2022
A call to action for translational sciences in COVID-19 and future pandemics
Translation Together, a transnational consortium of translational research organizations, reflects on successes and challenges in regional COVID-19 pandemic responses and proposes five priorities to improve preparedness for future global public health crises and improve the global approach to translational research and science.
Kanny K. Wan, Danielle Davis, Christine M. Cutillo

Nature Reviews Drug Discovery
Volume 21 Issue 3, March 2022
https://www.nature.com/nrd/volumes/21/issues/3

Comment | 28 January 2022
A call to action for translational sciences in COVID-19 and future pandemics
Translation Together, a transnational consortium of translational research organizations, reflects on successes and challenges in regional COVID-19 pandemic responses and proposes five priorities to improve preparedness for future global public health crises and improve the global approach to translational research and science.
Kanny K. Wan, Danielle Davis, Christine M. Cutillo

New England Journal of Medicine
March 17, 2022 Vol. 386 No. 11
https://www.nejm.org/toc/nejm/medical-journal

Perspective
A Malaria Vaccine for Africa — An Important Step in a Century-Long Quest P.L. Alonso and K.L. O’Brien
Malaria continues to devastate people’s health and livelihoods worldwide. In October 2021, the WHO for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission.

Original Articles

New England Journal of Medicine
March 17, 2022 Vol. 386 No. 11
https://www.nejm.org/toc/nejm/medical-journal

Original Articles
Homologous and Heterologous Covid-19 Booster Vaccinations R.L. Atmar and Others

New England Journal of Medicine
March 17, 2022 Vol. 386 No. 11
https://www.nejm.org/toc/nejm/medical-journal

Editorials
Audio Interview: Can We Make More Effective Covid-19 Vaccines? E.J. Rubin, L.R. Baden, and S. Morrissey

PLoS One
http://www.plosone.org/
[Accessed 19 Mar 2022]

Research Article
Use of oral polio vaccine and the incidence of COVID-19 in the world
Farrokh Habibzadeh, Konstantin Chumakov, Mohammad M. Sajadi, Mahboobeh Yadollahie, Kristen Stafford, Ashraf Simi, Shyamasundaran Kottilil, Iman Hafizi-Rastani, Robert C. Gallo
Research Article | published 17 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265562

PLoS One
http://www.plosone.org/
[Accessed 19 Mar 2022]

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
Kyra Hamilton, Martin S. Hagger
Research Article | published 14 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264784

PNAS – Proceedings of the National Academy of Sciences of the United States
March 1, 2022 | vol. 119 | no. 9
https://www.pnas.org/toc/pnas/119/9

February 22, 2022 | vol. 119 | no. 8
https://www.pnas.org/toc/pnas/119/8
Research Article February 7, 202 2Open Access
Testing fractional doses of COVID-19 vaccines
Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there are high expected social returns to investing in parallel in multiple approaches to accelerating vaccination. We argue there are high expected social returns to …
Witold Więcek, Amrita Ahuja,[…]Brandon Joel Tan

PNAS – Proceedings of the National Academy of Sciences of the United States
March 1, 2022 | vol. 119 | no. 9
https://www.pnas.org/toc/pnas/119/9

Research Article February 22, 2022 Open Access
Widespread use of National Academies consensus reports by the American public
In seeking to understand how to protect the public information sphere from corruption, researchers understandably focus on dysfunction. However, parts of the public information ecosystem function very well, and understanding this as well will help in …
Diana Hicks, Matteo Zullo,[…]Omar I. Asensio

Travel Medicine and Infectious Diseases
Volume 46 March–April 2022
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C

Review article Full text access
Travel vaccines throughout history
Androula Pavli, Helena C. Maltezou
Article 102278

Travel Medicine and Infectious Diseases
Volume 46 March–April 2022
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C

Research article Open access
Health and security risks of humanitarian aid workers during field missions: Experience of the International Red Cross
S.C. Guisolan, M. Ambrogi, A. Meeussen, F. Althaus, G. Eperon
Article 102275

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Short communication Open access
Conditionality of COVID-19 vaccine acceptance in European countries
Leonardo W. Heyerdahl, Muriel Vray, Benedetta Lana, Nastassia Tvardik, … Tamara Giles-Vernick
Pages 1191-1197

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Review article Open access
How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation
Mic McGoldrick, Thierry Gastineau, Diane Wilkinson, Cristiana Campa, … Samir Desai
Pages 1215-1222

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Review article Open access
How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation
Mic McGoldrick, Thierry Gastineau, Diane Wilkinson, Cristiana Campa, … Samir Desai
Pages 1223-1230

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Research article Full text access
COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population
Jana Shaw, Kathryn B. Anderson, Rachel E. Fabi, Carlie A. Thompson, … Andrea V. Shaw
Pages 1231-1237

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Research article Open access
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Yester F. Janssen, Eline A. Feitsma, Hendrikus H. Boersma, David G. Alleva, … Todd C. Zion
Pages 1253-1260

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Research article Abstract only
Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries
Keiko Pempho Msusa, Taryn Rogalski-Salter, Henshaw Mandi, Ralf Clemens
Pages 1261-1270

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Research article Open access
Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis
Frank G. Sandmann, Edwin van Leeuwen, Sibylle Bernard-Stoecklin, Itziar Casado, … Marc Baguelin
Pages 1306-1315

Vaccine
Volume 40, Issue 9 Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9

Research article Abstract only
Pertussis burden and acellular pertussis vaccine effectiveness in high risk children
Sarah Sheridan, Peter McIntyre, Bette Liu, Parveen Fathima, … Heather Gidding
Pages 1376-1382

Think Tanks

Brookings
http://www.brookings.edu/
Accessed 19 Mar 2022
[No new digest content identified]

Center for Global Development [to 19 Mar 2022]
https://www.cgdev.org/
Publications [Selected]
March 15, 2022
Learning Loss and Student Dropouts during the COVID-19 Pandemic: A Review of the Evidence Two Years after Schools Shut Down
Following the outbreak and spread of COVID-19 in 2020, schools around the world closed for significant periods of time. Many scholars provided projections of the likely impacts on educational outcomes, with potentially dire impacts on learning loss and—especially in low-income contexts–dropout rates. Now, two years after schools began shutting down, we identify 40 empirical studies directly estimating student learning loss (29 studies) or dropout rates (15 studies) for students in pre-primary, primary, or secondary school in countries at any income level.
Laura Moscoviz and David Evans

Chatham House [to 19 Mar 2022]
https://www.chathamhouse.org/
Accessed 19 Mar 2022
[No new digest content identified]

CSIS
https://www.csis.org/
Accessed 19 Mar 2022
Podcast Episode
Live From Munich: Dr. Richard Hatchett “Pandemic Preparedness Needs to Be Viewed as a Security Challenge”
March 15, 2022 | By J. Stephen Morrison

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 19 Mar 2022
March 16, 2022 News Release
States Are Planning for the End of the Continuous Enrollment Requirement in Medicaid After the COVID-19 Public Health Emergency Expires, But Many Have Not Made Key Decisions
As states plan for the end of the COVID-19 public health emergency, the resumption of eligibility redeterminations and disenrollments when the continuous Medicaid enrollment requirement is lifted could lead to coverage disruptions and losses, according to a new KFF 50-state survey. The requirement, a condition of states receiving enhanced federal…

March 15, 2022 News Release
Telehealth Continues to Account for More Than a Third of Outpatient Visits for Mental Health and Substance Use Services Well into the COVID-19 Pandemic
A new analysis from KFF and Epic Research finds that telehealth visits for outpatient mental health and substance use services went from virtually zero percent in 2019 prior to the COVID-19 pandemic to a peak of 40% in mid-2020 – and continued to account for more than a third (36%)…

Rand [to 19 Mar 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
[No new digest content identified]

Selected General Media

The Economist
This week A special edition on our coronavirus coverage
March 19th 2022
China is enduring its first big outbreak of the Omicron variant. At least 40m people are under some form of lockdown (though the authorities in some regions prefer the term “life on pause”). The restrictions pose a threat to China’s economic rebound and the world’s supply chains.

In Hong Kong the death rate from covid-19 is twice as large as the peak of Britain’s second wave in early 2021. Morgues are overflowing with victims and hospitals are struggling to cope.

The latest outbreak has delayed any relaxation of China’s zero-covid policy. Our Chaguan column explains why beating covid on the mainland will require less fear, and more vaccinations.

African countries are also struggling to get people jabbed against covid. Just 13% of the continent has been fully vaccinated. Africa has plenty of covid doses but the increased deliveries are exposing logistical defects in the distribution of vaccines.

To end on a sliver of good news: covid has led to other vaccine victories. Our data-driven coverage this week shows how a jab against malaria is arriving at last. It could save as many lives as covid has taken. And in our Asia section, we look at changing attitudes towards the human papillomavirus vaccine in Japan as inoculations become more routine.

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy